Man collapses during live broadcast from the Oval Office as Trump discusses new deal for obesity medication.
During a press conference held in the Oval Office on Thursday, an incident occurred that captured the attention of viewers nationwide when a pharmaceutical executive collapsed on live television. The event was part of a presentation regarding the Trump administration’s initiative to reduce the costs of certain obesity medications.
The unnamed executive was positioned behind the podium amidst a group of professionals as CEO of Eli Lilly, Dave Ricks, addressed the media. As the executive began to lose consciousness, multiple individuals, including Dr. Mehmet Oz, attempted to prevent him from falling, but he ultimately collapsed.
White House Press Secretary Karoline Leavitt later confirmed the incident, stating that a representative from one of the pharmaceutical companies fainted. She indicated that the White House Medical Unit responded swiftly to the situation and ensured that the individual was in stable condition.
The press conference was momentarily paused as reporters were escorted out of the Oval Office to allow medical personnel to attend to the individual concerned. The session resumed shortly thereafter, without the affected executive present.
President Trump addressed the incident upon the return of the press, acknowledging that one of the company representatives had felt light-headed and collapsed. He assured attendees that the individual was receiving appropriate medical care and expressed his apologies for the temporary disruption caused by the incident.
Initial reports incorrectly identified the individual as Gordon Findlay, an executive with Novo Nordisk, a company known for its weight loss medication Wegovy. However, Novo Nordisk later clarified that Findlay was not present at the press conference, although the company is a significant player in the obesity drug market.
At the center of the press conference was the discussion of lowering prices for obesity treatments. Eli Lilly announced it would reduce the cost of its weight loss drug, Zepbound, by per month. Zepbound is one of the leading alternatives in the growing market for obesity medications, competing with products like Wegovy, which can cost approximately 0 monthly and is often not covered by insurance plans.
The incident highlights the ongoing conversations and concerns surrounding the accessibility and affordability of weight loss medications, a topic that continues to receive considerable attention from both the public and political sphere as efforts are made to address the obesity epidemic in the United States.
Media News Source
